The present invention relates to eglin c variants which inhibit proteases, and in particular to eglin c mutants at adventitious contact sites. The present invention also relates to eglin c variants which comprise mutations in both adventitious contact sites and at reactive loop sites. The present invention further relates to methods of preparing the eglin c variants, and methods of using the eglin c variants for treatment of diseases including acute bacterial, viral, and fungal infections.

 
Web www.patentalert.com

< DNA sequences comprising dystrophin minigenes and methods of use thereof

< Targeted modification of chromatin structure

> Pharmaceutical materials and methods for their preparation and use

> Azabicyclic compounds for the treatment of disease

~ 00240